Some of those patients will experience refractory cancer – cancer that does not respond to initial treatment or becomes ...
T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...
Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...
Researchers have discovered a three-drug combination that enhances the generation of CAR-T cells, a type of cancer immunotherapy, and could improve CAR-T cell production for clinical treatments. The ...
CAR T-cell therapies have established themselves as a frequently very successful and overall promising treatment option for ...
Yescarta continued to demonstrate durable responses after a median follow-up of more than five years in patients with R/R indolent non-Hodgkin lymphoma.
Caregiving can take many forms, often requiring a profound shift in daily life. While navigating a disease is an immense challenge for patients, managing the emotional, logistical and personal burdens ...
Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without ...
UNC Lineberger researchers discovered a three-drug cocktail that enhances the production of T-memory stem cells (TSCMs) in ...
From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s ...
Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell ...